SBIR active for several years before the firm went public in July 2018, Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) is structured around discovery and development of novel therapeutics targeting peptide hormone receptors for treatment of endocrine-related diseases and cancers. The firm's programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost to achieve meaningful clinical data. Within an aggressive drug-hunter based culture, the defined objective of the firm is to help replenish the pharmaceutical pipeline and revitalize GPCR drug discovery by developing & applying next generation pharmacology tool. The strategy is to create value through building novel therapeutic assets & providing access to enabling technology for use outside of our internal therapeutic focus. Crinetics has assembled an experienced drug discovery team, exceptional academic collaborators and a network of proven service providers. The founding team has a strong track record together, including the discovery & development of elagolix, a first-in-class nonpeptide GnRH antagonist that has shown highly positive data in phase II clinical trials and is currently being prepared for registration studies. The firm's GPCR Dynamics Platform enables lead optimization based on fundamental pharmacologic properties typically only available for advanced clinical compounds. Crinetics' internal pipeline is focused on endocrine GPCRs that provide biochemical proof-of-concept in early clinical studies and offer significant potential advances for large markets. In addition to internal technology and pipeline development, Crinetics is currently seeking to partner with pharmaceutical and biotechnology companies to provide access to GPCR Dynamics Technology to support partner discovery projects.
